Eurofins/Product Safety Laboratories, Dayton, NJ, USA.
Toxicol Mech Methods. 2010 Jul;20(6):334-44. doi: 10.3109/15376516.2010.490966.
The present study was conducted to examine the safety of a novel plant-based calcium supplement, derived from marine algae and containing high levels of calcium, magnesium, and other bone supporting minerals (commercially known as AlgaeCal (AC)). The present study evaluated the broad-spectrum safety of AC using a variety of toxicological assays including acute oral, acute dermal, primary skin irritation, and primary eye irritation toxicity. Under the conditions of the study, the acute oral LD(50) of AC was found to be greater than 5000 mg/kg body weight in rats, while the single acute dermal LD(50) was greater than 2000 mg/kg body weight. The primary skin irritation index of AC was found to be 0.4 and classified as slightly irritating to the skin. In primary eye irritation studies, the maximum mean total score of AC was observed to be 13.7 and classified as mildly irritating to the eye. Furthermore, another independent set of studies was conducted to obtain preliminary data for the teratogenic effects of AC in pregnant rats likely to arise from repeated gestational exposure, via oral gavage, over a test period of implantation through gestation (gestation days 5-19). Under the conditions of this pilot study, the effect of daily administration of AC by oral gavage at dose levels of 0, 500, 2500, and 5000 mg/kg/day during gestation days 5-19 of a 21-day pregnancy has appeared to result in no adverse toxicological effects to the pregnant rat or its developing offspring. A slight, non-significant increase in the incidence of incomplete sterna ossification (5(th) center) was observed. Under the conditions of the study, a no-observed-adverse effect level (NOAEL) of 5000 mg/kg/day of AC during pregnancy of the rat was observed. Overall, no significant toxicities of AC were observed in these toxicity models. Therefore, the results from the current study demonstrate a broad-spectrum safety profile of AC.
本研究旨在考察一种新型植物源性钙补充剂的安全性,该补充剂源自海洋藻类,含有高水平的钙、镁和其他支持骨骼的矿物质(商业上称为藻钙(AC))。本研究使用各种毒理学检测方法评估了 AC 的广谱安全性,包括急性口服、急性皮肤刺激、原发性皮肤刺激和原发性眼睛刺激毒性。在研究条件下,AC 的急性口服 LD50 值大于 5000mg/kg 体重,而单次急性皮肤 LD50 值大于 2000mg/kg 体重。AC 的原发性皮肤刺激指数为 0.4,被归类为对皮肤轻度刺激。在原发性眼睛刺激研究中,AC 的最大平均总得分观察值为 13.7,被归类为对眼睛轻度刺激。此外,还进行了另一组独立的研究,以获得 AC 在怀孕大鼠中的致畸作用的初步数据,这些数据可能来自于通过口服灌胃在妊娠期间(着床期至妊娠第 19 天)进行的重复妊娠暴露。在这项初步研究的条件下,在妊娠第 5 天至第 19 天期间,每天通过口服灌胃给予 AC 剂量为 0、500、2500 和 5000mg/kg/天时,对怀孕大鼠或其发育后代没有出现不良的毒理学影响。观察到胸骨不完全骨化(第 5 中心)的发生率略有增加,但无统计学意义。在研究条件下,观察到大鼠妊娠期 AC 的无观察到不良作用水平(NOAEL)为 5000mg/kg/天。总体而言,在这些毒性模型中未观察到 AC 的显著毒性。因此,本研究的结果表明 AC 具有广泛的安全性特征。